Synthesis and Evaluation of a Macrocyclic Actinium‐225 Chelator, Quality Control and In Vivo Evaluation of 225Ac‐crown‐αMSH Peptide
- 25 June 2020
- journal article
- research article
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (50), 11435-11440
- https://doi.org/10.1002/chem.202002999
Abstract
Targeted alpha‐therapy (TAT) has great potential for treating a broad range of late stage cancers by delivering a focused and lethal radiation dose to tumors. Actinium‐225 ( 225 Ac) is an emerging alpha emitter suitable for TAT, however the availability of chelators for Ac remains limited to a small number of examples (DOTA and macropa). Herein we report a new Ac macrocyclic chelator named ‘crown ’, which binds quantitatively and rapidly (< 15 min) to Ac at ambient temperature. We synthesized 225 Ac‐crown‐αMSH, a peptide targeting the melanocortin 1 receptor (MC1R), specifically expressed in primary and metastatic melanoma. Biodistribution of 225 Ac‐crown‐αMSH showed favorable tumor‐to‐background ratios at 2 hours post injection in a preclinical model. In addition, we demonstrated dramatically different biodistrubution patterns of 225 Ac‐ crown‐αMSH when subjected to different latency times before injection. A combined quality control methodology involving HPLC, gamma spectroscopy and radioTLC is recommended.Keywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada (RGPIN 2016-04413)
This publication has 40 references indexed in Scilit:
- An Overview of Targeted Alpha Therapy with 225Actinium and 213BismuthCurrent Radiopharmaceuticals, 2018
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsNew England Journal of Medicine, 2017
- Targeted Radionuclide Therapy of Human TumorsInternational Journal of Molecular Sciences, 2015
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Alpha-Particle Emitting 213Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of OxygenationPLOS ONE, 2013
- Clinical radioimmunotherapy—the role of radiobiologyNature Reviews Clinical Oncology, 2011
- Actinium-225 in Targeted Alpha-Particle Therapeutic ApplicationsCurrent Radiopharmaceuticals, 2011
- Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluationHepatology, 2011
- MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide TherapyJournal of Nuclear Medicine, 2010
- An overview of current clinical experience with strontium-89 (Metastron®)The Prostate, 1994